Danaher Co. (NYSE:DHR) is Brasada Capital Management LP’s 7th Largest Position

Brasada Capital Management LP cut its holdings in shares of Danaher Co. (NYSE:DHR) by 1.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 65,901 shares of the conglomerate’s stock after selling 1,116 shares during the quarter. Danaher comprises approximately 2.8% of Brasada Capital Management LP’s portfolio, making the stock its 7th largest holding. Brasada Capital Management LP’s holdings in Danaher were worth $15,808,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of DHR. Norges Bank purchased a new stake in shares of Danaher during the 4th quarter valued at about $2,130,740,000. Raymond James Financial Inc. bought a new position in Danaher during the fourth quarter valued at approximately $391,172,000. Capital World Investors boosted its holdings in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock worth $1,460,215,000 after purchasing an additional 1,566,658 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock worth $213,452,000 after purchasing an additional 916,513 shares during the last quarter. Finally, Parnassus Investments LLC grew its position in Danaher by 31.8% in the 4th quarter. Parnassus Investments LLC now owns 3,105,388 shares of the conglomerate’s stock worth $712,842,000 after purchasing an additional 749,136 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $192.06 on Wednesday. The stock has a 50-day moving average price of $201.41 and a 200 day moving average price of $225.77. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $171.00 and a 12-month high of $281.70. The stock has a market capitalization of $137.27 billion, a P/E ratio of 36.38, a P/E/G ratio of 2.66 and a beta of 0.86.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Equities research analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.67%. The ex-dividend date is Friday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is 24.24%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on DHR. JPMorgan Chase & Co. dropped their price target on Danaher from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Tuesday. Robert W. Baird set a $231.00 target price on Danaher in a research report on Wednesday, April 16th. Stifel Nicolaus raised shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 price target for the company in a research report on Friday, March 14th. Barclays raised their price objective on shares of Danaher from $205.00 to $215.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $277.00 target price (down from $299.00) on shares of Danaher in a report on Thursday, January 30th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $271.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.